Evidence map›Paper›PMID 34861603›Full record

ArticleJournal of infection and public health2022

Risk factors for COVID-19 progression and mortality in hospitalized patients without pre-existing comorbidities.

Weifang Liu, Chengzhang Yang, Yuan-Gao Liao, Feng Wan, Lijin Lin, Xuewei Huang, Bing-Hong Zhang, Yufeng Yuan, Peng Zhang, Xiao-Jing Zhang and 3 more

Open access · goldAbstract readMulticenter Study
In one paragraph

Article in Journal of infection and public health, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed, 1 pooled it
3.0field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 1 synthesis or guideline pooled it, 52 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Distinctive features and prognostic utility of neutrophil in severe patients withFrontiers in cellular and infection microbiology · 2024
    Article
  12. Article
  13. International journal of molecular sciences · 2023
    Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 1 country.

Weifang LiuDepartment of Neurology, Huanggang Central Hospital, Huanggang, China; Huanggang Institute of Translational Medicine, Huanggang, China; School of Basic Medical Sciences, Wuhan University, Wuhan, China; Institute of Model Animal of Wuhan University, Wuhan, China.
Chengzhang YangInstitute of Model Animal of Wuhan University, Wuhan, China; Department of Cardiology, Renmin Hospital, Wuhan University, Wuhan, China.
Yuan-Gao LiaoDepartment of Neurology, Huanggang Central Hospital, Huanggang, China; Huanggang Institute of Translational Medicine, Huanggang, China.
Feng WanDepartment of Neurology, Huanggang Central Hospital, Huanggang, China; Huanggang Institute of Translational Medicine, Huanggang, China.
Lijin LinInstitute of Model Animal of Wuhan University, Wuhan, China; Department of Cardiology, Renmin Hospital, Wuhan University, Wuhan, China.
Xuewei HuangInstitute of Model Animal of Wuhan University, Wuhan, China; Department of Cardiology, Renmin Hospital, Wuhan University, Wuhan, China.
Bing-Hong ZhangNeonatology Department, Renmin Hospital of Wuhan University, Wuhan, China.
Yufeng YuanDepartment of Hepatobiliary and Pancreatic Surgery, Zhongnan Hospital of Wuhan University, Wuhan, China.
Peng ZhangSchool of Basic Medical Sciences, Wuhan University, Wuhan, China; Institute of Model Animal of Wuhan University, Wuhan, China.
Xiao-Jing ZhangSchool of Basic Medical Sciences, Wuhan University, Wuhan, China; Institute of Model Animal of Wuhan University, Wuhan, China.
Zhi-Gang SheInstitute of Model Animal of Wuhan University, Wuhan, China; Department of Cardiology, Renmin Hospital, Wuhan University, Wuhan, China.
Lei WangHuanggang Institute of Translational Medicine, Huanggang, China; Department of Neurosurgery, Huanggang Central Hospital, Huanggang, China. Electronic address: wanglei@hgyy.org.cn.
Hongliang LiHuanggang Institute of Translational Medicine, Huanggang, China; Institute of Model Animal of Wuhan University, Wuhan, China; Department of Cardiology, Renmin Hospital, Wuhan University, Wuhan, China; Medical Science Research Center, Zhongnan Hospital of Wuhan University, Wuhan, China. Electronic address: lihl@whu.edu.cn.
Wuhan University · CNHuanggang Central Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCoronavirus disease 2019 (COVID-19) pandemic continues to escalate intensively worldwide. Massive studies on general populations with SARS-CoV-2 infection have revealed that pre-existing comorbidities were a major risk factor for the poor prognosis of COVID-19. Notably, 49-75% of COVID-19 patients had no comorbidities, but this cohort would also progress to severe COVID-19 or even death. However, risk factors contributing to disease progression and death in patients without chronic comorbidities are largely unknown; thus, specific clinical interventions for those patients are challenging.

methodsA multicenter, retrospective study based on 4806 COVID-19 patients without chronic comorbidities was performed to identify potential risk factors contributing to COVID-19 progression and death using LASSO and a stepwise logistic regression model.

resultsAmong 4806 patients without pre-existing comorbidities, the proportions with severe progression and mortality were 34.29% and 2.10%, respectively. The median age was 47.00 years [interquartile range, 36.00-56.00], and 2162 (44.99%) were men. Among 51 clinical parameters on admission, age ≥ 47, oxygen saturation < 95%, increased lactate dehydrogenase, neutrophil count, direct bilirubin, creatine phosphokinase, blood urea nitrogen levels, dyspnea, increased blood glucose and prothrombin time levels were associated with COVID-19 mortality in the entire cohort. Of the 3647 patients diagnosed with non-severe COVID-19 on admission, 489(13.41%) progressed to severe disease. The risk factors associated with COVID-19 progression from non-severe to severe illness were increased procalcitonin levels, SpO2 < 95%, age ≥ 47, increased LDH, activated partial thromboplastin time levels, decreased high-density lipoprotein cholesterol levels, dyspnea and increased D-dimer levels.

conclusionsCOVID-19 patients without pre-existing chronic comorbidities have specific traits and disease patterns. COVID-19 accompanied by severe bacterial infections, as indicated by increased procalcitonin levels, was highly associated with disease progression from non-severe to severe. Aging, impaired respiratory function, coagulation dysfunction, tissue injury, and lipid metabolism dysregulation were also associated with disease progression. Once factors for multi-organ damage were elevated and glucose increased at admission, these findings indicated a higher risk for mortality. This study provides information that helps to predict COVID-19 prognosis specifically in patients without chronic comorbidities.

Indexed as

COVID-19HumansMaleMiddle AgedOxygen SaturationRetrospective StudiesRisk FactorsSARS-CoV-2COVID-19MortalityRisk factorsSeverityWithout comorbidities

Identifiers

PMID34861603
PMCPMC8598256
OpenAlexW3216941935

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.